1.A Case of Langerhans Cell Sarcoma Presenting as Submandibular Gland Mass
Geonho LEE ; Kunho SONG ; Ki Wan PARK ; Bon Seok KOO
Korean Journal of Otolaryngology - Head and Neck Surgery 2019;62(9):520-523
Langerhans cell sarcoma is a rare, proliferative tumor of Langerhans cells, which shows cytologic characteristics and clinical features of malignant tumor. Langerhans cell sarcoma primarily occurs in lymph nodes, skin, lung, liver, and spleen. However, very few cases have been reported in the head and neck region. Because of its rarity, an optimal treatment approach is unknown; however, Langerhans cell sarcoma grows aggressively and shows a poor prognosis, such that a more aggressive and multi-modality treatment approach is necessary. Here, we report the case of a 36-year-old male with Langerhans cell sarcoma, who presented with a mass in the submandibular gland area and was treated with wide excision and postoperative radiotherapy.
Adult
;
Head
;
Humans
;
Langerhans Cell Sarcoma
;
Langerhans Cells
;
Liver
;
Lung
;
Lymph Nodes
;
Male
;
Neck
;
Prognosis
;
Radiotherapy
;
Sarcoma
;
Skin
;
Spleen
;
Submandibular Gland
2.A Case of Langerhans Cell Sarcoma Presenting as Submandibular Gland Mass
Geonho LEE ; Kunho SONG ; Ki Wan PARK ; Bon Seok KOO
Korean Journal of Otolaryngology - Head and Neck Surgery 2019;62(9):520-523
Langerhans cell sarcoma is a rare, proliferative tumor of Langerhans cells, which shows cytologic characteristics and clinical features of malignant tumor. Langerhans cell sarcoma primarily occurs in lymph nodes, skin, lung, liver, and spleen. However, very few cases have been reported in the head and neck region. Because of its rarity, an optimal treatment approach is unknown; however, Langerhans cell sarcoma grows aggressively and shows a poor prognosis, such that a more aggressive and multi-modality treatment approach is necessary. Here, we report the case of a 36-year-old male with Langerhans cell sarcoma, who presented with a mass in the submandibular gland area and was treated with wide excision and postoperative radiotherapy.
3.Clinical Characteristics of Temporal Bone Metastases
Kunho SONG ; Ki Wan PARK ; Jae Hyung HEO ; Ik Chan SONG ; Yong Ho PARK ; Jin Woong CHOI
Clinical and Experimental Otorhinolaryngology 2019;12(1):27-32
OBJECTIVES: The purposes of this study were to evaluate the clinical characteristics of temporal bone metastasis (TBM) and to determine whether the characteristics differed according to primary malignancy. METHODS: We retrospectively analyzed data on 20 patients diagnosed with TBM between January 2000 and January 2017. Demographics, the period from diagnosis of primary malignancy to TBM diagnosis, the period from TBM diagnosis to death, the type and staging of primary malignancy, otologic manifestations, and TBM sites were assessed. After the primary malignancies were divided into solid cancers and hematologic malignancies, each parameter was compared between the two groups. RESULTS: The most common primary malignancy with TBM was lung cancer (45%). The most common otologic symptoms and signs were facial palsy (30.5%) and hearing loss (30.5%). The temporal squama (23%) and the facial nerve (20%) were the most commonly involved. Most TBMs occurred late in the disease process after the primary malignancy first metastasized to other organs. Hematologic malignancies metastasized significantly more frequently to the external auditory canal and the middle ear/mastoid compared to solid cancers (P=0.001 and P=0.004, respectively). CONCLUSION: If otologic manifestations such as facial palsy and hearing loss are presented in patients at advanced stages of malignancy, TBM of primary malignancy should be suspected. In addition, hematologic malignancies tend to metastasize to the external auditory canal and the middle ear cleft more commonly than solid cancers do.
Demography
;
Diagnosis
;
Ear Canal
;
Ear, Middle
;
Facial Nerve
;
Facial Paralysis
;
Head and Neck Neoplasms
;
Hearing Loss
;
Hematologic Neoplasms
;
Humans
;
Leukemia
;
Lung Neoplasms
;
Neoplasm Metastasis
;
Retrospective Studies
;
Temporal Bone
4.Identification of Pathogenic Variants in the CHM Gene in Two Korean Patients With Choroideremia.
Kunho BAE ; Ju Sun SONG ; Chung LEE ; Nayoung K D KIM ; Woong Yang PARK ; Byoung Joon KIM ; Chang Seok KI ; Sang Jin KIM
Annals of Laboratory Medicine 2017;37(5):438-442
Choroideremia is a rare X-linked disorder causing progressive chorioretinal atrophy. Affected patients develop night blindness with progressive peripheral vision loss and eventual blindness. Herein, we report two Korean families with choroideremia. Multimodal imaging studies showed that the probands had progressive loss of visual field with characteristic chorioretinal atrophy, while electroretinography demonstrated nearly extinguished cone and rod responses compatible with choroideremia. Sanger sequencing of all coding exons and flanking intronic regions of the CHM gene revealed a novel small deletion at a splice site (c.184_189+3delTACCAGGTA) in one patient and a deletion of the entire exon 9 in the other. This is the first report on a molecular genetic diagnosis of choroideremia in Korean individuals. Molecular diagnosis of choroideremia should be widely adopted for proper diagnosis and the development of new treatment modalities including gene therapy.
Atrophy
;
Blindness
;
Choroideremia*
;
Clinical Coding
;
Diagnosis
;
Electroretinography
;
Exons
;
Genetic Therapy
;
Humans
;
Introns
;
Molecular Biology
;
Multimodal Imaging
;
Night Blindness
;
Visual Fields
5.Nucleotide-Binding Oligomerization Domain-Like Receptor 3 Inflammasome Inhibition by MCC950 Reduces the Lipopolysaccharide-Induced Interleukin-1β in Cultured Dispersed Nasal Polyp Cells
Soo Kyoung PARK ; Rui-Ning HAN ; Jun XU ; Sun Hee YEON ; Sung Bok LEE ; Kunho SONG ; Jenny BYUN ; Ki Sang RHA ; Yong Min KIM
Korean Journal of Otolaryngology - Head and Neck Surgery 2020;63(5):206-215
Background and Objectives:
The nucleotide-binding oligomerization domain-like receptor (NLRP) 3 is known as a member of the NLR family, and it has been confirmed that the NLRP3 inflammasome is associated with various diseases such as asthma, inflammatory bowel disease, metabolic disorders and multiple sclerosis, as well as other auto-immune and auto-inflammatory diseases. However, the role of NLRP3 in chronic rhinosinusitis with nasal polyps (CRSwNP) has not yet been explored.Subjects and Method Forty-four specimens of nasal polyps and 25 specimens of uncinate processes were collected from patients with chronic rhinosinusitis with nasal polyps, and 25 specimens of uncinate tissues were collected from patients who underwent other rhino-surgeries. The western blot assay was employed to analyze the expression of NLRP3; interleukin (IL)-1β and IL-17A were detected using immunohistochemistry and real-time polymerase chain reaction. The production of lipopolysaccharide (LPS) induced IL-1β and IL-17A with or without the NLRP3 inflammasome inhibitor (MCC950) was measured using an enzyme linked immunosorbent assay in cultured dispersed nasal polyp cells.
Results:
NLRP3 showed a high level of expression in nasal polyps than in the control group (p<0.01). The expression of IL-1β and IL-17A was significantly higher in nasal polyps in the CRSwNP group than in the control group (p<0.05). LPS-induced production of IL-1β was significantly suppressed by treatment with the NLRP3 inflammasome inhibitor (p<0.05).
Conclusion
The NLRP3 inflammasome plays an essential role in the pathogenesis of CRSwNP, and thus MCC950 can be considered a prospective therapeutic for NLRP3 inflammasome-mediated inflammation in nasal polyps. Our data provide new evidence that IL-17A is involved in inflammasome-associated inflammation in nasal polyps.